Full-Time
Confirmed live in the last 24 hours
Dialysis treatment and training solutions
$110kAnnually
Junior, Mid
Indiana, USA + 1 more
More locations: Michigan, USA
The job is focused on the territories of Michigan and Indiana.
You match the following Outset Medical's candidate preferences
Employers are more likely to interview you if you match these preferences:
Outset Medical improves dialysis treatment by offering the Tablo system, which integrates with electronic medical record (EMR) platforms to streamline workflows and manage patient data effectively. They provide educational programs and hands-on training for dialysis professionals, including a Vascular Access Program and a Bridge Program to support facilities transitioning to in-house dialysis services. Outset Medical stands out by delivering a comprehensive approach to dialysis care across hospitals, outpatient clinics, and home settings. Their goal is to enhance the quality of care for dialysis patients through effective training and integrated technology.
Company Size
501-1,000
Company Stage
IPO
Total Funding
$542.8M
Headquarters
San Jose, California
Founded
2010
Help us improve and share your feedback! Did you find this helpful?
Medical, dental, & vision
Life Insurance/AD&D
FSA & HSA
401k
Parental leave
Pet insurance
Tuition reimbursement
PTO
Company events
In addition to the private placement, Outset secured a $100 million term loan from Perceptive Advisors, with an option for $25 million more.
Outset Medical announced a $169 million private placement financing, issuing 843,908 shares of Series A Non-Voting Convertible Preferred Stock at $200 per share. The company also secured up to $125 million in debt financing maturing in 2030, with plans to retire $200 million in prior debt. The financing was led by PFM Health Sciences and Perceptive Advisors. Outset reported unaudited Q4 revenue of $29 million and 2024 revenue of $113 million. The transactions are expected to close by January 8, 2025.
Berman Tabacco announces that it has filed a new class action complaint against Outset Medical, Inc. with an Expanded Class Period.
To achieve this milestone, Outset partnered with Corsec, completing the validation at a Level 1 as seen in certificate #4812.
Then, on August 2, 2023, Outset Medical issued a press release announcing a "Shipment Pause of TabloCart with Prefiltration Pending 510(k) Clearance."